Stocktoria
VACCINEX, INC. VCNX
VACCINEX, INC. (VCNX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2024 revenue was $601,000 at a -3100.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VCNX | VACCINEX, INC. | 3/9 | — | — | — |
| ELAB | PMGC Holdings Inc. | 2/9 | — | — | — |
| VYNE | VYNE Therapeutics Inc. | 2/9 | — | — | — |
| BTAI | BioXcel Therapeutics, Inc. | 2/9 | — | — | — |
| SLN | Silence Therapeutics plc | 1/9 | -12.42 | — | -98.7% |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
| MREO | Mereo BioPharma Group plc | 3/9 | — | — | — |
About VACCINEX, INC.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
FAQ
Is VCNX financially healthy?
VACCINEX, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does VCNX pay a dividend?
No, VACCINEX, INC. does not currently pay a dividend.
How profitable is VCNX?
In FY2024, VACCINEX, INC. had a net margin of -3100.5%.
Is VCNX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VACCINEX, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2024-12-31. Facts plus Stocktoria's own computed scores — not investment advice.